Headache News and Research

Latest Headache News and Research

Merck receives Health Canada approval for GARDASIL to treat HPV in women upto age 45

Today, Merck announced that Health Canada has extended the indication of GARDASIL in women up to the age of 45. Merck's HPV vaccine is now approved for girls and women nine through 45 years of age for the prevention of cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by the Human Papillomavirus types 6, 11, 16, 18. Previously, GARDASIL was approved in girls and women nine through 26.

26 Apr 2011

GSK receives FDA approval for Lamictal XR to treat partial seizures

GlaxoSmithKline announced today that the U.S. Food and Drug Administration has approved Lamictal XR Extended-Release Tablets for conversion to monotherapy in patients 13 years and older with partial seizures taking one anti-epileptic drug.

26 Apr 2011

Nausea and vomiting are most feared of all chemotherapy-related side effects

PediatRx, Inc. today commented on studies which reveal that chemotherapy-induced nausea and vomiting is one of the most feared of all chemotherapy-related side effects. The fear of nausea and subsequent vomiting is many times so significant that patients can develop a condition known as 'anticipatory' nausea, where the patient becomes nauseous primarily as a result of the fear of becoming nauseous.

25 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

AstraZeneca announces U.S. availability of vandetanib for rare medullary thyroid cancer

AstraZeneca today announced that the orphan drug vandetanib is now available to U.S. patients for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

25 Apr 2011

Bayer's oral contraceptives may increase risk of blood clots, stroke or heart attack

Bayer HealthCare Pharmaceuticals, Inc. is aware of two studies published today in The British Medical Journal, ONLINE FIRST.

25 Apr 2011

Noninvasive Masimo carboxyhemoglobin can effectively screen ED patients for CO poisoning

Masimo announced today that a new study published in this month's issue of the peer-reviewed journal, Annals of Emergency Medicine, demonstrates that noninvasive Masimo carboxyhemoglobin measurements provide an "effective means for screening at-risk populations for CO poisoning" with "acceptable bias and precision" compared to invasive blood gas analysis.

25 Apr 2011

FDA approves Sanofi Pasteur's meningococcal vaccine

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra, to include a two-dose schedule for infants and children 9 months through 23 months of age.

25 Apr 2011

'Iceman' influences autonomic nervous system and immune response

At the Radboud University Nijmegen Medical Centre, professor of experimental intensive care medicine dr. Peter Pickkers and his team have performed research on "Iceman" Wim Hof. Hof claims that he can influence his autonomic nervous system and immune response through concentration and meditation.

22 Apr 2011

Physiotherapy Associates inaugurates new clinic in Grand Haven, MI

Physiotherapy Associates, the nation's foremost provider of outpatient rehabilitation services, recently opened a new physical therapy clinic in Grand Haven, MI.

22 Apr 2011

Salix Pharmaceuticals receives three U.S. patents relating to rifaximin

Salix Pharmaceuticals, Ltd. today announced that the U.S. Patent and Trademark Office has issued three patents relating to rifaximin.

21 Apr 2011

HHS will award quality bonuses to some Medicare advantage plans

In a policy shift critics see as political, the Health and Human Services department has decided to award quality bonuses to hundreds of Medicare Advantage plans rated merely average.

21 Apr 2011

$2.3 million of malaria medicines stolen

According to the Global Fund to Fight AIDS, Tuberculosis and Malaria, malaria medications valued at almost $2.3 million may have been stolen from government-run distribution centers in Africa and other locations.

20 Apr 2011

First Edition: April 20, 2011

Today's headlines include reports about new poll results showing that Americans oppose cuts to Medicare as a means to deal with the debt problem.

20 Apr 2011

Minimizing neurological side effects in high-grade glioma patients may improve survival

Minimizing neurological side effects in patients with high-grade glioma from chemoradiation may result in improved patient survival, a new study from radiation oncologists at the Kimmel Cancer Center at Jefferson suggests. These findings were reported in the April issue of the British Journal of Cancer.

20 Apr 2011

Rituxan receives FDA approval for treating two rare diseases

The U.S. Food and Drug Administration today approved Rituxan (rituximab), in combination with glucocorticoids (steroids), to treat patients with Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis).

20 Apr 2011

Acorda receives patent for AMPYRA tablets to improve walking in MS patients

Acorda Therapeutics, Inc. today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 11/010,828 entitled "Sustained Release Aminopyridine Composition."

20 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

Hangovers affect surgeon's performance

A new study has shown that excessive alcohol consumption, even on the previous day, appears to be associated with changes in some surgical skills performed on virtual reality simulator testing the following day. The study appeared in the April issue of Archives of Surgery, one of the JAMA/Archives journals.

19 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011